ReviewCancer2020
Clinical trial design: Past, present, and future in the context of big data and precision medicine.
Review in Cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 47 citations in OpenAlex.
- MsDGCN: multi-scale diffusion graph convolutional network for the prediction of drug-disease association.Journal of computer-aided molecular design · 2026Article
- Need for NAMs: A systematic evidence synthesis revealing over half a century of drug development failure.NAM journal · 2026Article
- Review
- Diagnostics and Therapy for Malignant Tumors.Biomedicines · 2024Review
- Review
- Review
- Factors Associated with Inclusion of Japan in Phase I Multiregional Clinical Trials in Oncology.Therapeutic innovation & regulatory science · 2024Article
- Nanoengineering Solutions for Cancer Therapy: Bridging the Gap between Clinical Practice and Translational Research.Journal of clinical medicine · 2024Article
- Therapeutic developments in pancreatic cancer.Nature reviews. Gastroenterology & hepatology · 2024Review
- Trainee Evaluations of Preparedness for Clinical Trials in Medical Oncology-A National Questionnaire.Current oncology (Toronto, Ont.) · 2023Article
- Exploratory Analysis of Drug Lag in New Oncology Drugs Between Japan and the US.Therapeutic innovation & regulatory science · 2023Article
- How can we deliver on the promise of precision medicine in oncology and beyond? A practical roadmap for action.Health science reports · 2023Article
- In silico cancer immunotherapy trials uncover the consequences of therapy-specific response patterns for clinical trial design and outcome.Nature communications · 2023Article
- Biomarker-Driven Oncology Clinical Trials: Novel Designs in the Era of Precision Medicine.Journal of the advanced practitioner in oncology · 2023Review
- The Promise of Nanotechnology in Personalized Medicine.Journal of personalized medicine · 2022Review
- Proteomics, Personalized Medicine and Cancer.Cancers · 2021Review
- Low expression of CHRDL1 and SPARCL1 predicts poor prognosis of lung adenocarcinoma based on comprehensive analysis and immunohistochemical validation.Cancer cell international · 2021Article
- Review
- Advanced Computational Methodologies Used in the Discovery of New Natural Anticancer Compounds.Frontiers in pharmacology · 2021Review
- Machine learning in the prediction of cancer therapy.Computational and structural biotechnology journal · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical trials are fundamental for advances in cancer treatment. The traditional framework of phase 1 to 3 trials is designed for incremental advances between regimens. However, our ability to understand and treat cancer has evolved with the increase in drugs targeting an expanding array of therapeutic targets, the development of progressively comprehensive data sets, and emerging computational analytics, all of which are reshaping our treatment strategies. A more robust linkage between drugs and underlying cancer biology is blurring historical lines that define trials on the basis of cancer type. The complexity of the molecular basis of cancer, coupled with manifold variations in clinical status, is driving the individually tailored use of combinations of precision targeted drugs. This approach is spawning a new era of clinical trial types. Although most care is delivered in a community setting, large centers support real-time multi-omic analytics and their integrated interpretation by using machine learning in the context of real-world data sets. Coupling the analytic capabilities of large centers to the tailored delivery of therapy in the community is forging a paradigm that is optimizing service for patients. Understanding the importance of these evolving trends across the health care spectrum will affect our treatment of cancer in the future and is the focus of this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.